KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBT (2017 - 2025)

Historic EBT for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$15.4 million.

  • Aquestive Therapeutics' EBT fell 3420.8% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 9660.61%. This contributed to the annual value of -$44.2 million for FY2024, which is 47902.95% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' EBT is -$15.4 million, which was down 3420.8% from -$13.5 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' EBT peaked at $8.1 million during Q1 2023, and registered a low of -$28.9 million during Q4 2021.
  • Its 5-year average for EBT is -$12.0 million, with a median of -$12.8 million in 2024.
  • As far as peak fluctuations go, Aquestive Therapeutics' EBT tumbled by 42986.29% in 2021, and later surged by 16102.87% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' EBT (Quarter) stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then skyrocketed by 35.15% to -$8.0 million in 2023, then tumbled by 113.1% to -$17.1 million in 2024, then rose by 9.51% to -$15.4 million in 2025.
  • Its last three reported values are -$15.4 million in Q3 2025, -$13.5 million for Q2 2025, and -$22.9 million during Q1 2025.